Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Regulatory News (BQE)

  • There is currently no data for BQE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Contract

2 Dec 2011 07:00

RNS Number : 2066T
Bioquell PLC
02 December 2011
 



 

2 December, 2011

BIOQUELL PLC

Award of a £1.2 million development contract by General Dynamics as part of the new SV vehicle for the UK Ministry of Defence

Bioquell PLC (LSE: BQE) ("Bioquell") - provider of specialist low temperature, residue-free bio-decontamination and filtration technologies to the healthcare, life sciences and defence sectors - announces that it has been awarded a £1.2 million development contract relating to the new reconnaissance vehicle being developed by General Dynamics for the UK Ministry of Defence.

Background

General Dynamics UK LLC, a subsidiary of the US General Dynamics Group, has been awarded a contract by the UK Ministry of Defence for the Specialist Vehicles Programme Demonstration, Manufacture and In-Service Support for the Reconnaissance Block 1 Vehicles and Common Base Platform (the "SV Programme").

Bioquell UK Limited, a subsidiary of Bioquell PLC, develops and manufactures, among other things, Chemical, Biological, Radiological and Nuclear ("CBRN") filtration systems as well as Environmental Control Systems ("ECS").

Contract award

General Dynamics - Santa Bárbara Sistemas, S.A., a Spanish subsidiary of the General Dynamics Group, has awarded Bioquell UK Limited a development contract worth approximately £1.2 million relating to ECS and CBRN systems for the demonstration phase of the SV Programme.

Once this initial development contract has been fulfilled, it is expected that contracts relating to the manufacture and in-service phases will be awarded, with shipments expected to start in 2014 and expected to run for at least five years.

Commenting on this contract award, Nick Adams, Group Chief Executive of Bioquell PLC, said:

"We are extremely pleased to have been awarded this prestigious development contract relating to the British Army's new reconnaissance vehicle."

 

- Ends -

Enquiries:

 

Bioquell PLC 01264 835 900

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer / Finance Director

 

Notes to editors:

§ Bioquell is a UK-headquartered, international technology company with two divisions:

o Bio-decontamination which sells specialist bio-decontamination products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC which provides UK corporates with specialist Testing, Regulatory and Compliance services - many of which are required by national and international regulations.

§ Bioquell's gas phase bio-decontamination technology uses hydrogen peroxide vapour ("HPV") - which is highly efficacious at eradicating micro-organisms such as bacteria, viruses and fungi at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen at the end of the bio-decontamination process.

§ Bioquell's specialist filtration technology including peroxide catalysis and chemical, biological, radiological and nuclear ("CBRN") filtration systems used principally in the defence sector is highly complementary to the defence application for its HPV technology which is used to decontaminate biological and chemical warfare agents.

§ Bioquell's bio-decontamination technology:

o is used by bio-pharmaceutical, biologics, biotechnology and research institutions to provide sterile equipment and/or sterile working environments - which is of particular interest to organisations working with biologically-derived drugs;

o is used to eradicate drug resistant organisms associated with Hospital Acquired Infection as well as problematic viruses from the hospital environment. Independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces the rates of hospital acquired infection;

o was selected by the United States Department of Defense for the JSSED programme to decontaminate sensitive equipment against biological and chemical warfare agents;

o benefits from a number of granted or pending patent filings in the UK and internationally; and

o is used in other sectors where bioburden can create significant problems including, for example, the food industry.

§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore and China.

§ TRaC sells its specialist testing services to the product development and engineering departments of a broad range of companies and organisations, principally based in the UK, with a particular focus on the aerospace, military and telecoms sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTFSSFMFFFSEFE
Date   Source Headline
26th Apr 20174:02 pmRNSResult of AGM
26th Apr 201711:44 amRNSAGM Statement
6th Apr 201710:54 amRNSDirector/PDMR Shareholding
31st Mar 20171:54 pmRNSTotal Voting Rights
28th Mar 20179:34 amRNSDirectorate Change
27th Mar 201711:15 amRNSDirector/PDMR Shareholding, Exercise of Options
24th Mar 201711:38 amRNSAnnual Financial Report
14th Mar 20172:17 pmRNSStatement re Purchase of Own Shares
13th Mar 20179:41 amRNSStatement re Share Buyback
10th Mar 201710:18 amRNSDirector/PDMR Shareholding
7th Mar 20177:00 amRNSFinal Results
19th Jan 20177:00 amRNSPre-close statement
3rd Jan 20178:35 amRNSStatement re Issue of shares
28th Dec 201611:55 amRNSHolding(s) in Company
5th Dec 201611:13 amRNSPurchase of own shares
24th Nov 20161:33 pmRNSResult of Meeting
8th Nov 20168:14 amRNSBlock listing Interim Review
7th Nov 20167:00 amRNSStatement re Share Buy Back
4th Nov 201611:15 amRNSNotice of GM
21st Oct 201612:31 pmRNSHolding(s) in Company
21st Oct 20168:57 amRNSDirector Declaration
6th Oct 20165:04 pmRNSDirector/PDMR Shareholding
1st Sep 20161:08 pmRNSDirector/PDMR Shareholding
24th Aug 20161:15 pmRNSDoc re. Board Committee Changes
24th Aug 20169:38 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
24th Aug 20167:05 amRNSFurther re Strategic Review
24th Aug 20167:00 amRNSHalf-year Report
23rd Aug 20169:25 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
22nd Aug 20169:54 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
19th Aug 20169:33 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
18th Aug 20169:07 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
17th Aug 20169:22 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
16th Aug 20169:21 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
15th Aug 20169:05 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
12th Aug 20169:25 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
11th Aug 20169:15 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
10th Aug 20165:46 pmRNSForm 8.3 - Bioquell PLC
10th Aug 20169:04 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
9th Aug 20165:49 pmRNSForm 8.3 - Bioquell PLC
9th Aug 20169:09 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
8th Aug 20169:20 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
5th Aug 20165:42 pmRNSForm 8.3 - Bioquell PLC
5th Aug 20169:25 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
4th Aug 20165:27 pmRNSForm 8.3 - Bioquell PLC
4th Aug 20162:57 pmRNSForm 8.3 - Bioquell PLC
4th Aug 20169:28 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
3rd Aug 201610:09 amRNSForm 8.3 - Bioquell Plc
3rd Aug 20169:22 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
2nd Aug 20169:14 amRNSForm 8.5 (EPT/RI) - Bioquell Plc
1st Aug 20169:15 amRNSForm 8.5 (EPT/RI) - Bioquell Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.